Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences (Nasdaq: SLDB) announced on January 5, 2026 an inducement grant of 7,000 restricted stock units (RSUs) to a newly hired employee under the company’s 2024 Inducement Stock Incentive Plan.

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced on January 5, 2026 an inducement grant of 7,000 restricted stock units (RSUs) to a newly hired employee under the company’s 2024 Inducement Stock Incentive Plan. The RSUs vest in four equal annual installments on each one-year anniversary of the grant date through the fourth anniversary, subject to the employee’s continued service.

The grant was made as an inducement material to the employee’s acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Argus Jan 6 session

+3.00% close to close Open Argus

Details

News Market Reaction – SLDB

On Jan 6, the first trading day after this news, SLDB closed 3.00% above the previous close.

Data tracked by StockTitan Argus for the Jan 6 session.

Key Figures

Inducement RSUs: 7,000 RSUs Vesting schedule: 4 equal installments Vesting horizon: 4th anniversary +1 more

Inducement RSUs

7,000 RSUs

Grant to one newly hired employee under 2024 Inducement Plan

Vesting schedule

4 equal installments

RSUs vest annually over four years, subject to continued service

Vesting horizon

4th anniversary

Final RSU tranche vests on the fourth anniversary of grant date

Nasdaq rule

Rule 5635(c)(4)

Governs inducement equity grants for new employees

Historical Context

5 past events · Latest: 2025-12-16

5 events

1. 2025-12-16

   Screening panel update

   24h Move

   +1.9%

   Duchenne added to U.S. RUSP, supporting earlier detection and treatment access.

2. 2025-12-08

   Pipeline data presentations

   24h Move

   -1.0%

   New data presentations on AAV-SLB101 and cardiac gene therapy pipeline.

3. 2025-12-01

   Inducement RSU grants

   24h Move

   -2.1%

   23,284 RSUs granted to new hires under 2024 Inducement Plan.

4. 2025-12-01

   Regulatory designation

   24h Move

   -4.0%

   FDA Rare Pediatric Disease designation for SGT-212 gene therapy for FA.

5. 2025-11-17

   Licensing agreement

   24h Move

   +2.4%

   Non-exclusive worldwide license of AAV-SLB101 to Andelyn Biosciences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement stock incentive plan

3 terms

restricted stock units financial

"announced grants of 7,000 restricted stock units (“RSUs”) to one newly hired"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHARLESTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 7,000 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Solid Biosciences (SLDB) announce on January 5, 2026 about stock awards?

Solid Biosciences announced a grant of 7,000 RSUs to a newly hired employee, with four equal annual vesting installments.

What is the vesting schedule for the 7,000 RSUs granted by SLDB on January 5, 2026?

The RSUs vest in four equal installments on each one-year anniversary of the grant date through the fourth anniversary, subject to continued service.

Under which plan were the inducement RSUs for SLDB granted on January 5, 2026?

The award was made under the company’s 2024 Inducement Stock Incentive Plan.

Why did Solid Biosciences grant RSUs as an inducement on January 5, 2026?

The company said the grant was an inducement material to the employee’s acceptance of employment in line with Nasdaq Listing Rule 5635(c)(4).

Does the SLDB January 5, 2026 RSU grant immediately transfer shares to shareholders?

No; the 7,000 RSUs vest over four years and are subject to the employee’s continued service, so they do not immediately transfer shares.

How should investors view the SLDB January 5, 2026 inducement grant in terms of shareholder impact?

The announcement notes a 7,000 RSU grant to one hire; material shareholder effects were not specified in the disclosure.